Literature DB >> 6428906

Lipoprotein abnormalities in patients with early primary biliary cirrhosis.

A Aly, K Carlson, C Johansson, P Kirstein, S Rössner, L Wallentin.   

Abstract

In twelve females with early forms of primary biliary cirrhosis (PBC) serum lipoproteins, the intravenous fat tolerance test ( IVFTT ) and the lecithin: cholesterol acyl transferase (LCAT) rate were determined and compared to healthy controls. The cholestatic LDL (LP-X) test was negative in all cases. PBC patients had lower very low density lipoprotein TG concentrations than controls and had levels of (high-density lipoprotein) HDL-TG, -cholesterol and -phospholipids that were about 50% higher than in controls. In PBC the HDL2-cholesterol concentration was double but the HDL3-cholesterol concentration was 60% of control values (P less than 0.001 for both). The LCAT rate and the IVFTT value did not differ between the groups. A typical finding on agarose gel electrophoresis was the appearance of a slow-moving alpha-band. Several interpretations of these results are possible. In PBC the hepatic lipase activity may be impaired leading to a shift of the HDL2/HDL3 relation. The transport of HDL2 to the liver lipase site may also be affected and HDL3 production reduced due to malabsorption in the intestine.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6428906     DOI: 10.1111/j.1365-2362.1984.tb02106.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  3 in total

1.  Hypercholesterolemia in primary biliary cirrhosis is no risk factor for atherosclerosis.

Authors:  A Propst; T Propst; M Lechleitner; F Hoppichler; H Kathrein; W Vogel; G Judmaier; E Knapp; H Braunsteiner
Journal:  Dig Dis Sci       Date:  1993-02       Impact factor: 3.199

2.  Lipoprotein pattern and plasma lipoprotein lipase activities in patients with primary biliary cirrhosis. Relationship with increase of HDL2 fraction in Lp-X-positive and Lp-X-negative subjects.

Authors:  G Baldo-Enzi; M R Baiocchi; M Grotto; A R Floreani; M Zagolin; M Chiaramonte; F Cera; R Fellin
Journal:  Dig Dis Sci       Date:  1988-10       Impact factor: 3.199

3.  Atorvastatin does not improve liver biochemistries or Mayo Risk Score in primary biliary cirrhosis.

Authors:  Carmen M Stanca; Nancy Bach; Jorge Allina; Carol Bodian; Henry Bodenheimer; Joseph A Odin
Journal:  Dig Dis Sci       Date:  2008-04-05       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.